Biomarker Analysis: Pharmacodynamic Monitoring

Rapid and robust immunoassays

Biomarker analysis provides prognostic, predictive, pharmacodynamic (PD), safety, or surrogate endpoint information for therapeutic interventions. 

Precise and robust fit-for-purpose biomarker immunoassay methods are needed to support preclinical and clinical biotherapeutic development, with single biomarker assay development typically occurring prior to preclinical studies of a drug candidate. Gyrolab immunoassays provide fully automated, robust assay performance with high precision, a wide dynamic range, and straightforward custom assay development, supporting biomarker analysis in regulated environments. 

The recent introduction of the Gyrolab Bioaffy™ 4000 CD expands Gyrolab assay sensitivity for a more powerful solution to biomarker analysis down to low pg/mL levels.

• Robust and reliable biomarker quantification
  Reproducible data across operators and instruments and over long time periods
  Straightforward validation for regulated studies
  Software designed for 21 CFR Part 11 compliance
• Fully automated, rapid time to results
  About one hour run times with automated assay workflow 
  Limit hands-on and in-lab time  
• High sensitivity & wide dynamic range
  Low pg/mL sensitivity
  3-4 logs dynamic range 
• Open platform for flexible assay development
  Flexible assay development for your immunoassay design and reagents
  Gyrolab assay protocols available for cytokine analysis
• Biomarker assays run precisely with Gyroplex^® panels
  Independent reactions with high sensitivity and quality results 

Biomarker quantification using Gyrolab platform positively impacts productivity in the development of therapeutics.

Gyrolab assay protocols are available for the cytokine and other biomarkers below:

Non-human primate